# A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

Source: https://onco.cc/trials/nct06839066/  
OnCo record `nct06839066` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HLX43 DOSE 1 in nasopharyngeal carcinoma, run by Shanghai Henlius Biotech, now recruiting.

## Summary

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy is a phase 2 interventional study registered as NCT06839066 by Shanghai Henlius Biotech, with 70 participants planned, started 2025-04-02 and due to reach its primary completion in 2026-11-22. Interventions recorded: HLX43 DOSE 1, HLX43 DOSE 2 and HLX43 DOSE 3.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06839066
- Phase: 2
- Setting: A Phase II Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma (NPC) Failed or Intolerance to Second-line Therapy
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06839066: https://clinicaltrials.gov/study/NCT06839066

## Connected records

- cancers: [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct06839066.json